FDA grants new Genmab drug priority review status
The US health authority FDA has accepted Genmab and Seagen's application for a biologics license application relating to their product tisotumab vedotin.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Friday evening, partners Genmab and Seagen announced that the US Food and Drug Administration (FDA) has accepted their biologics license application (BLA) in the US for tisotumab vedotin for treating recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
